Literature DB >> 33956992

Prognostic models for predicting relapse or recurrence of major depressive disorder in adults.

Andrew S Moriarty1,2, Nicholas Meader3,4, Kym Ie Snell5, Richard D Riley5, Lewis W Paton1, Carolyn A Chew-Graham6, Simon Gilbody1,2, Rachel Churchill3,4, Robert S Phillips3, Shehzad Ali1,7, Dean McMillan1,2.   

Abstract

BACKGROUND: Relapse (the re-emergence of depressive symptoms after some level of improvement but preceding recovery) and recurrence (onset of a new depressive episode after recovery) are common in depression, lead to worse outcomes and quality of life for patients and exert a high economic cost on society. Outcomes can be predicted by using multivariable prognostic models, which use information about several predictors to produce an individualised risk estimate. The ability to accurately predict relapse or recurrence while patients are well (in remission) would allow the identification of high-risk individuals and may improve overall treatment outcomes for patients by enabling more efficient allocation of interventions to prevent relapse and recurrence.
OBJECTIVES: To summarise the predictive performance of prognostic models developed to predict the risk of relapse, recurrence, sustained remission or recovery in adults with major depressive disorder who meet criteria for remission or recovery. SEARCH
METHODS: We searched the Cochrane Library (current issue); Ovid MEDLINE (1946 onwards); Ovid Embase (1980 onwards); Ovid PsycINFO (1806 onwards); and Web of Science (1900 onwards) up to May 2020. We also searched sources of grey literature, screened the reference lists of included studies and performed a forward citation search. There were no restrictions applied to the searches by date, language or publication status . SELECTION CRITERIA: We included development and external validation (testing model performance in data separate from the development data) studies of any multivariable prognostic models (including two or more predictors) to predict relapse, recurrence, sustained remission, or recovery in adults (aged 18 years and over) with remitted depression, in any clinical setting. We included all study designs and accepted all definitions of relapse, recurrence and other related outcomes. We did not specify a comparator prognostic model. DATA COLLECTION AND ANALYSIS: Two review authors independently screened references; extracted data (using a template based on the CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS)); and assessed risks of bias of included studies (using the Prediction model Risk Of Bias ASsessment Tool (PROBAST)). We referred any disagreements to a third independent review author. Where we found sufficient (10 or more) external validation studies of an individual model, we planned to perform a meta-analysis of its predictive performance, specifically with respect to its calibration (how well the predicted probabilities match the observed proportions of individuals that experience the outcome) and discrimination (the ability of the model to differentiate between those with and without the outcome). Recommendations could not be qualified using the GRADE system, as guidance is not yet available for prognostic model reviews. MAIN
RESULTS: We identified 11 eligible prognostic model studies (10 unique prognostic models). Seven were model development studies; three were model development and external validation studies; and one was an external validation-only study. Multiple estimates of performance measures were not available for any of the models and, meta-analysis was therefore not possible. Ten out of the 11 included studies were assessed as being at high overall risk of bias. Common weaknesses included insufficient sample size, inappropriate handling of missing data and lack of information about discrimination and calibration. One paper (Klein 2018) was at low overall risk of bias and presented a prognostic model including the following predictors: number of previous depressive episodes, residual depressive symptoms and severity of the last depressive episode. The external predictive performance of this model was poor (C-statistic 0.59; calibration slope 0.56; confidence intervals not reported). None of the identified studies examined the clinical utility (net benefit) of the developed model. AUTHORS'
CONCLUSIONS: Of the 10 prognostic models identified (across 11 studies), only four underwent external validation. Most of the studies (n = 10) were assessed as being at high overall risk of bias, and the one study that was at low risk of bias presented a model with poor predictive performance. There is a need for improved prognostic research in this clinical area, with future studies conforming to current best practice recommendations for prognostic model development/validation and reporting findings in line with the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement.
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2021        PMID: 33956992      PMCID: PMC8102018          DOI: 10.1002/14651858.CD013491.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  93 in total

Review 1.  Remission onset and relapse in depression. An 18-month prospective study of course for 100 first admission patients.

Authors:  D O'Leary; F Costello; N Gormley; M Webb
Journal:  J Affect Disord       Date:  2000 Jan-Mar       Impact factor: 4.839

Review 2.  Prevalence and predictors of recurrence of major depressive disorder in the adult population.

Authors:  F Hardeveld; J Spijker; R De Graaf; W A Nolen; A T F Beekman
Journal:  Acta Psychiatr Scand       Date:  2009-12-11       Impact factor: 6.392

3.  Reporting of artificial intelligence prediction models.

Authors:  Gary S Collins; Karel G M Moons
Journal:  Lancet       Date:  2019-04-20       Impact factor: 79.321

4.  A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses.

Authors:  Dean Langan; Julian P T Higgins; Dan Jackson; Jack Bowden; Areti Angeliki Veroniki; Evangelos Kontopantelis; Wolfgang Viechtbauer; Mark Simmonds
Journal:  Res Synth Methods       Date:  2018-09-06       Impact factor: 5.273

5.  Prediction of recurrence in recurrent depression: a 5.5-year prospective study.

Authors:  Mascha C ten Doesschate; Claudi L H Bockting; Maarten W J Koeter; Aart H Schene
Journal:  J Clin Psychiatry       Date:  2010-08       Impact factor: 4.384

6.  Longitudinal hypothalamic-pituitary-adrenal axis trait and state effects in recurrent depression.

Authors:  Anja Lok; Roel J T Mocking; Henricus G Ruhé; Ieke Visser; Maarten W J Koeter; Johanna Assies; Claudi L H Bockting; Miranda Olff; Aart H Schene
Journal:  Psychoneuroendocrinology       Date:  2011-11-17       Impact factor: 4.905

7.  How durable is the effect of low intensity CBT for depression and anxiety? Remission and relapse in a longitudinal cohort study.

Authors:  Shehzad Ali; Laura Rhodes; Omar Moreea; Dean McMillan; Simon Gilbody; Chris Leach; Mike Lucock; Wolfgang Lutz; Jaime Delgadillo
Journal:  Behav Res Ther       Date:  2017-04-18

8.  Empirically derived decision trees for the treatment of late-life depression.

Authors:  Carmen Andreescu; Benoit H Mulsant; Patricia R Houck; Ellen M Whyte; Sati Mazumdar; Alexandre Y Dombrovski; Bruce G Pollock; Charles F Reynolds
Journal:  Am J Psychiatry       Date:  2008-05-01       Impact factor: 18.112

9.  Development and validation of a clinical prediction tool to estimate the individual risk of depressive relapse or recurrence in individuals with recurrent depression.

Authors:  Nicola S Klein; Gea A Holtman; Claudi L H Bockting; Martijn W Heymans; Huibert Burger
Journal:  J Psychiatr Res       Date:  2018-06-08       Impact factor: 4.791

10.  Prediction of relapse in melancholic depressive patients in a 2-year follow-up study with corticotropin releasing factor test.

Authors:  Luis Pintor; Xavier Torres; Victor Navarro; M A Jesús Martinez de Osaba; Silvia Matrai; Cristobal Gastó
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-01-23       Impact factor: 5.067

View more
  5 in total

1.  Prognostic models for predicting relapse or recurrence of major depressive disorder in adults.

Authors:  Andrew S Moriarty; Nicholas Meader; Kym Ie Snell; Richard D Riley; Lewis W Paton; Carolyn A Chew-Graham; Simon Gilbody; Rachel Churchill; Robert S Phillips; Shehzad Ali; Dean McMillan
Journal:  Cochrane Database Syst Rev       Date:  2021-05-06

2.  Six-year prognosis of anxiety and depression caseness and their comorbidity in a prospective population-based adult sample.

Authors:  Olivia Stålner; Steven Nordin; Guy Madison
Journal:  BMC Public Health       Date:  2022-08-15       Impact factor: 4.135

3.  Predicting Remission among Perinatal Women with Depression in Rural Pakistan: A Prognostic Model for Task-Shared Interventions in Primary Care Settings.

Authors:  Ahmed Waqas; Siham Sikander; Abid Malik; Najia Atif; Eirini Karyotaki; Atif Rahman
Journal:  J Pers Med       Date:  2022-06-27

4.  The development and validation of a prognostic model to PREDICT Relapse of depression in adult patients in primary care: protocol for the PREDICTR study.

Authors:  Andrew S Moriarty; Lewis W Paton; Kym I E Snell; Richard D Riley; Joshua E J Buckman; Simon Gilbody; Carolyn A Chew-Graham; Shehzad Ali; Stephen Pilling; Nick Meader; Bob Phillips; Peter A Coventry; Jaime Delgadillo; David A Richards; Chris Salisbury; Dean McMillan
Journal:  Diagn Progn Res       Date:  2021-07-02

5.  A Patient Stratification Approach to Identifying the Likelihood of Continued Chronic Depression and Relapse Following Treatment for Depression.

Authors:  Rob Saunders; Zachary D Cohen; Gareth Ambler; Robert J DeRubeis; Nicola Wiles; David Kessler; Simon Gilbody; Steve D Hollon; Tony Kendrick; Ed Watkins; David Richards; Sally Brabyn; Elizabeth Littlewood; Debbie Sharp; Glyn Lewis; Steve Pilling; Joshua E J Buckman
Journal:  J Pers Med       Date:  2021-12-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.